Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3264201 | 0.90 | L3MBTL1 (0.36) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL3259083 | 0.88 | ADH1A (0.37) | ALDH1A1L3MBTL1 | |
| SCHEMBL3263457 | 0.84 | ADH1C (0.35) | ALDH1A1L3MBTL1 | |
| SCHEMBL3261528 | 0.81 | ADH1B (0.33) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL3264062 | 0.74 | L3MBTL1 (0.41) | ALDH1A1L3MBTL1KDM4EMEN1NPC1 | |
| SCHEMBL3259464 | 0.72 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL3264991 | 0.72 | ADH1A (0.39) | ALDH1A1L3MBTL1KDM4EMEN1NPC1 | |
| SCHEMBL4616663 | 0.71 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL3263172 | 0.71 | L3MBTL1 (0.39) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL3262162 | 0.71 | ALDH1A1 (0.35) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | ALDH1A1 1501/4885L3MBTL1 874/4885KDM4E 4157/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | ALDH1A1 3543/4885L3MBTL1 1100/4885KDM4E 3885/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | ALDH1A1 1151/4885L3MBTL1 999/4885KDM4E 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.